What's The Link Between Antihypertensive Drugs And Cancer

1. What's The Link Between Antihypertensive Drugs And Cancer The risk of cancer from antihypertensive drugs has been much debated, many researchers are interested in the link between them. Do antihypertensive drugs increase the risk of cancer? Is there any connection between them? Recently, the late breaking research was presented on Aug 31th, at ESC Congress 2020. The research shows there is no evidence that antihypertensive drugs increase the risk of cancer, according to the most extensive study conducted on the topic. The potential link between antihypertensive drugs and cancer has been debated for more than 40 years. The evidence that the use of antihypertensive drugs increases or decreases the risk of cancer has been inconsistent and conflicting. It was the largest study on cancer outcomes among participants in randomised trials investigating antihypertensive medication - approximately 260,000 people in 31 trials. Investigators of all trials were asked to provide information about which participants had cancer. Much of this information has not been released before, which made the current analysis the most detailed yet. Five antihypertensive drug classes were investigated separately. They are

2. angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta blockers, calcium channel blockers (CCBs) and diuretics. The researchers estimated the impact of each drug on the risk of developing any type of cancer, dying from cancer, and developing breast, colorectal, lung, prostate and skin cancer. Before participating in the trial, they also examined whether there were any differences according to age, gender, body size, smoking status and previous antihypertensive drugs. Over an average of four years, about 15,000 people were diagnosed with cancer. The researchers found there is no evidence that the use of any antihypertensive drug increased the risk of cancer. This finding was consistent regardless of age, gender, body size, smoking status and previous antihypertensive drugs use. Compare each drug category with all other control groups, including placebo, standard treatment, and other drug categories. There was no any individual drug category has a significant effect on overall cancer risk. The hazard ratio (HR) for any cancer was 0.99 (95% confidence interval [CI]) 0.94-1.04) with ACE inhibitors, 0.97 (95% CI 0.93-1.02) with ARBs, 0.98 (95% CI 0.89-1.08) with beta blockers, 1.06 (95% CI 1.01-1.11) with CCBs and 1.01 (95% CI 0.95-1.07) with diuretics. In statistical terms, these effect sizes were not significantly different from each other, so there was no evidence that any class of antihypertensive drugs increased the risk of cancer. Similarly, there was no evidence that any classes of antihypertensive drugs had an effect on the incidence of developing breast, colorectal, lung, prostate or skin cancer. When participants were followed throughout each trial, there was no indication that the risk of cancer increased with the duration of these treatments. "Our study has addressed an ongoing controversy about whether antihypertensive drugs increase the risk of cancer. We used the largest individual-level randomised evidence on antihypertensive drug to date and provide evidence for the safety of antihypertensive drugs in relation to cancer." said Ms. Emma Copland, a Study Author and Epidemiologist, University of Oxford, UK. Huateng Pharma, a professional pharmaceutical company with a 34000m² industrial park, has large scale manufacturing capabilities at our modern facility. We supply many kinds of pharmaceutical intermediates such

3. as anti-cancer & anti-hypertensive & anti-virus APIs and intermediates to customers all over the world. We are able to provide scale-up production with capacities varying from gram to kilograms and multi tons. Source: European Society of Cardiology